


PHARMACEUTICAL 2019



ENANTA PHARMACEUTICALS INC Rank 6 of 363





PHARMACEUTICAL 2019



ENANTA PHARMACEUTICALS INC Rank 6 of 363



The relative strengths and weaknesses of ENANTA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENANTA PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 115% points. The greatest weakness of ENANTA PHARMACEUTICALS INC is the variable Other Compr. Net Income, reducing the Economic Capital Ratio by 0.33% points.

The company's Economic Capital Ratio, given in the ranking table, is 345%, being 308% points above the market average of 37%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 380,389 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 16,025 |
| Liabilities, Non-Current | 2,895 |
| Other Assets | 25,464 |
| Other Compr. Net Income | -286 |
| Other Expenses | 21,165 |
| Other Liabilities | 1,628 |
| Other Net Income | 4,793 |
| Other Revenues | 206,625 |
| Property and Equipment | 8,374 |
| Research and Development | 94,856 |
| Selling, General and Administrative Expense | 23,441 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 414,227 |
| Liabilities | 20,548 |
| Expenses | 139,462 |
| Revenues | 206,625 |
| Stockholders Equity | 393,679 |
| Net Income | 71,956 |
| Comprehensive Net Income | 71,813 |
| Economic Capital Ratio | 345% |